Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.

Erin D Lewis,Amanda Piano,Thomas A Tompkins,Renu Bhardwaj,Joseph M Antony,David C Crowley,Malkanthi Evans

doi:10.3390/nu12041159

Erin D Lewis, Amanda Piano + Show 5 more

Open Access

https://doi.org/10.3390/nu12041159

Copy DOI

Journal: Nutrients	Publication Date: Apr 21, 2020
Citations: 42	License type: CC BY 4.0

Affiliation: Lallemand (Canada)

Abstract

Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes.

Highlights

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders (GI) worldwide, affecting approximately 11% of the global population [1]
Four participants were removed from the L. paracasei group due to consumption of magnesium throughout the study (n = 1), use of antibiotics (n = 1), or insufficient compliance (n = 2)
Three participants were excluded from the B. longum group for consumption of NSAIDs (n = 1), antibiotics (n = 1), and laxatives (n = 1)

Summary

Introduction

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders (GI) worldwide, affecting approximately 11% of the global population [1]. IBS is characterized by the co-occurrence of abdominal pain or discomfort, changes in bowel habits, and defecation [2]. The physical symptoms of IBS are variable in severity, ranging from unpleasant to debilitating, and as a result, patients’ psychological well-being and quality of life can be adversely affected in more severe cases. This variability in the severity of IBS symptoms, coupled with our incomplete understanding of its pathophysiology, often results in extended delays for patients before. Nutrients 2020, 12, 1159 receiving a diagnosis. This leads to inconsistencies in the efficacy of symptom management regimes

Objectives

Methods

Results

Conclusion